CoChat

Colony-stimulating factor 1 receptor (CSF1R) signaling in injured neurons facilitates protection and survival

Open access

The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.

Abstract

Colony-stimulating factor 1 (CSF1) and interleukin-34 (IL-34) are functional ligands of the CSF1 receptor (CSF1R) and thus are key regulators of the monocyte/macrophage lineage. We discovered that systemic administration of human recombinant CSF1 ameliorates memory deficits in a transgenic mouse model of Alzheimer’s disease. CSF1 and IL-34 strongly reduced excitotoxin-induced neuronal cell loss and gliosis in wild-type mice when administered systemically before or up to 6 h after injury. These effects were accompanied by maintenance of cAMP responsive element–binding protein (CREB) signaling in neurons rather than in microglia. Using lineage-tracing experiments, we discovered that a small number of neurons in the hippocampus and cortex express CSF1R under physiological conditions and that kainic acid–induced excitotoxic injury results in a profound increase in neuronal receptor expression. Selective deletion of CSF1R in forebrain neurons in mice exacerbated excitotoxin-induced death and neurodegeneration. We conclude that CSF1 and IL-34 provide powerful neuroprotective and survival signals in brain injury and neurodegeneration involving CSF1R expression on neurons.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1084/jem.20120412

Cites

80 of 80 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Systemic CSF1 improves cognitive function in hAPP transgenic mice. (A) hAPP transgenic mice and their nTG littermates (n = 9–10 mice per genotype, age 5.5–6.5 mo) were injected with 800 µg/kg CSF1 or PBS three times a week. After 10 wk of treatment, spatial cognitive function in mice was assessed using the Morris water maze. (B–E) hAPP mice and nTG littermates (18–20 mo old) were assessed by water maze in hidden platform tests (B) and a probe trial 24 h later (C). The mice were then randomly divided into CSF1 or PBS groups (n = 6–8 mice per genotype). After 1 mo of treatment, mice were tested again with a water maze hidden platform test (D) and a probe trial (E). The target quadrant was quadrant 1 in C and E. Bars are mean ± SEM. *, P < 0.05; **, P < 0.01 compared by ANOVA and Bonferroni post-hoc test. Each experiment was performed once.
Figure 1. Systemic CSF1 improves cognitive function in hAPP transgenic mice. (A) hAPP transgenic mice and their nTG littermates (n = 9–10 mice per genotype, age 5.5–6.5 mo) were injected with 800 µg/kg CSF1 or PBS three times a week. After 10 wk of treatment, spatial cognitive function in mice was assessed using the Morris water maze. (B–E) hAPP mice and nTG littermates (18–20 mo old) were assessed by water maze in hidden platform tests (B) and a probe trial 24 h later (C). The mice were then randomly divided into CSF1 or PBS groups (n = 6–8 mice per genotype). After 1 mo of treatment, mice were tested again with a water maze hidden platform test (D) and a probe trial (E). The target quadrant was quadrant 1 in C and E. Bars are mean ± SEM. *, P < 0.05; **, P < 0.01 compared by ANOVA and Bonferroni post-hoc test. Each experiment was performed once.CC BY-NC-SA · PubMed Central
Figure 2. Systemic administration of CSF1 inhibits KA-induced astrogliosis in reporter mice. (A) Experimental design and injury models of excitotoxicity. To induce excitotoxic neurodegeneration, KA was administered systemically (subcutaneously, SQ) in FVB/N and stereotaxically into the hippocampus in C57BL/6 mice. Neurodegeneration was analyzed 5 d later. To determine the effective time window of CSF1 and IL-34 application, CSF1 and IL-34 (single-bolus) were administered at different time points in relation to KA injury, 2 and 24 h before and 2, 6, and 12 h after KA administration. An example of one treatment (24 h before) is shown (top two panels). To study the time course of expression of endogenous CSF1 or its receptor, CSF1R, mice were analyzed at 6 h, 24 h, 3 d, and 5 d (bottom). BLI, bioluminescence imaging. (B–D) GFAP-luc mice (FVB/N background, 2 mo old) were lesioned with 20 mg/kg KA, and bioluminescence was recorded longitudinally at the indicated time points in each mouse. (B) Representative images from two independent experiments showing increased bioluminescence signals over the brain after KA injury (top) and the reduction by CSF1 treatment (applied 24 h before KA; bottom). (C and D) Bioluminescence is expressed as fold induction over baseline in mice treated with CSF1 at 2 or 24 h before KA (C) or at 2, 6, or 12 h after KA (D). Baseline was measured 1 d before KA administration for each mouse. Bars are mean ± SEM (n = 4–7 mice). *, P < 0.05 compared by ANOVA and Bonferroni post-hoc test. Each experiment (condition) was performed once in D.
Figure 2. Systemic administration of CSF1 inhibits KA-induced astrogliosis in reporter mice. (A) Experimental design and injury models of excitotoxicity. To induce excitotoxic neurodegeneration, KA was administered systemically (subcutaneously, SQ) in FVB/N and stereotaxically into the hippocampus in C57BL/6 mice. Neurodegeneration was analyzed 5 d later. To determine the effective time window of CSF1 and IL-34 application, CSF1 and IL-34 (single-bolus) were administered at different time points in relation to KA injury, 2 and 24 h before and 2, 6, and 12 h after KA administration. An example of one treatment (24 h before) is shown (top two panels). To study the time course of expression of endogenous CSF1 or its receptor, CSF1R, mice were analyzed at 6 h, 24 h, 3 d, and 5 d (bottom). BLI, bioluminescence imaging. (B–D) GFAP-luc mice (FVB/N background, 2 mo old) were lesioned with 20 mg/kg KA, and bioluminescence was recorded longitudinally at the indicated time points in each mouse. (B) Representative images from two independent experiments showing increased bioluminescence signals over the brain after KA injury (top) and the reduction by CSF1 treatment (applied 24 h before KA; bottom). (C and D) Bioluminescence is expressed as fold induction over baseline in mice treated with CSF1 at 2 or 24 h before KA (C) or at 2, 6, or 12 h after KA (D). Baseline was measured 1 d before KA administration for each mouse. Bars are mean ± SEM (n = 4–7 mice). *, P < 0.05 compared by ANOVA and Bonferroni post-hoc test. Each experiment (condition) was performed once in D.CC BY-NC-SA · PubMed Central
Figure 3. Systemic CSF1 attenuates KA-induced neurodegeneration and microgliosis. (A–J) 2-mo-old FVB/N mice were lesioned with 20 mg/kg KA (subcutaneous injection) or injected with PBS as control and sacrificed 5 d later. Recombinant 800 µg/kg CSF1 was injected i.p. once 24 h before KA. KA-induced neuronal injury was assessed by cresyl violet staining (A and B), calbindin immunostaining (C and D), and NPY immunostaining (E and F), and microglial activation was assessed by CD68 (G and H) or Iba-1 (I and J) immunostaining. Representative images from three independent experiments are shown from hippocampi of mice: control (nonlesioned, left) or KA lesioned and treated with PBS (middle) or CSF1 (right). Bars, 200 µm. (K and L) Systemic administration of CSF1 after KA lesion reduces neurodegeneration. KA-lesioned mice were treated with CSF1 at 2, 6, and 12 h after injury. The mice were sacrificed at day 5. Excitotoxic injury was assessed by cresyl violet staining (K) and CD68 immunostaining (L). Bars are mean ± SEM (n = 4–7 mice/group). *, P < 0.05; **, P < 0.01 compared by ANOVA and Bonferroni post-hoc test. Similar results were obtained from two independent experiments.
Figure 3. Systemic CSF1 attenuates KA-induced neurodegeneration and microgliosis. (A–J) 2-mo-old FVB/N mice were lesioned with 20 mg/kg KA (subcutaneous injection) or injected with PBS as control and sacrificed 5 d later. Recombinant 800 µg/kg CSF1 was injected i.p. once 24 h before KA. KA-induced neuronal injury was assessed by cresyl violet staining (A and B), calbindin immunostaining (C and D), and NPY immunostaining (E and F), and microglial activation was assessed by CD68 (G and H) or Iba-1 (I and J) immunostaining. Representative images from three independent experiments are shown from hippocampi of mice: control (nonlesioned, left) or KA lesioned and treated with PBS (middle) or CSF1 (right). Bars, 200 µm. (K and L) Systemic administration of CSF1 after KA lesion reduces neurodegeneration. KA-lesioned mice were treated with CSF1 at 2, 6, and 12 h after injury. The mice were sacrificed at day 5. Excitotoxic injury was assessed by cresyl violet staining (K) and CD68 immunostaining (L). Bars are mean ± SEM (n = 4–7 mice/group). *, P < 0.05; **, P < 0.01 compared by ANOVA and Bonferroni post-hoc test. Similar results were obtained from two independent experiments.CC BY-NC-SA · PubMed Central
Figure 4. Systemically administered IL-34 attenuates KA-induced neurodegeneration and microgliosis. (A–J) 2-mo-old FVB/N mice were lesioned with 20 mg/kg KA (subcutaneous injection) and sacrificed 5 d later. 100 µg/kg IL-34 was injected i.p. once 2 h before KA. KA-induced neuronal injury was assessed by cresyl violet staining (A and B), calbindin (C and D), and NeuN (E and F) immunostaining, and microglial activation was assessed by CD68 (G and H) or Iba-1 (I and J) immunostaining. Representative images from two independent experiments are shown from hippocampi of mice treated with PBS (left) or IL-34 (right). Bars, 200 µm. Bars in B, D, F, H, and J are mean ± SEM (n = 4 mice/group) from one out of two independent experiments. *, P < 0.05; **, P < 0.01 compared by Student’s t test. (K and L) KA-lesioned mice were treated with IL-34 at 2 and 6 h after injury. The mice were sacrificed at day 5. Excitotoxic injury was assessed by NeuN immunostaining (K) and cresyl violet staining (L). The experiment was performed once. Bars are mean ± SEM (n = 5 mice/group). *, P < 0.05 compared by ANOVA and Bonferroni post-hoc test.
Figure 4. Systemically administered IL-34 attenuates KA-induced neurodegeneration and microgliosis. (A–J) 2-mo-old FVB/N mice were lesioned with 20 mg/kg KA (subcutaneous injection) and sacrificed 5 d later. 100 µg/kg IL-34 was injected i.p. once 2 h before KA. KA-induced neuronal injury was assessed by cresyl violet staining (A and B), calbindin (C and D), and NeuN (E and F) immunostaining, and microglial activation was assessed by CD68 (G and H) or Iba-1 (I and J) immunostaining. Representative images from two independent experiments are shown from hippocampi of mice treated with PBS (left) or IL-34 (right). Bars, 200 µm. Bars in B, D, F, H, and J are mean ± SEM (n = 4 mice/group) from one out of two independent experiments. *, P < 0.05; **, P < 0.01 compared by Student’s t test. (K and L) KA-lesioned mice were treated with IL-34 at 2 and 6 h after injury. The mice were sacrificed at day 5. Excitotoxic injury was assessed by NeuN immunostaining (K) and cresyl violet staining (L). The experiment was performed once. Bars are mean ± SEM (n = 5 mice/group). *, P < 0.05 compared by ANOVA and Bonferroni post-hoc test.CC BY-NC-SA · PubMed Central
Figure 5. Endogenous CSF1 is up-regulated in neurons after excitotoxic brain injury. (A–C) Wild-type FVB/N or CSF1-null Csf1op/op mice (2 mo old) were lesioned with 20 mg/kg KA (subcutaneous injection) and sacrificed 6 h, 1 d, and 3 d later. Brain sections were immunostained with an antibody against CSF1. (A) Representative images from wild-type controls (no injury), KA lesioned and sacrificed at 6 h, KA lesioned and sacrificed at 24 h, or Csf1op/op mice. (B) Quantification of CSF1 immunoreactivity in the hippocampus after KA injury (n = 4–6 mice/group). Error bars indicate SEM. (C) Colocalization of CSF1 and neuronal marker NeuN but not microglial marker (Iba-1) after KA lesion (6 h). Bars: (A) 200 µm; (C) 20 µm. (D) Inverse correlation (Pearson correlation) of CSF1 immunoreactivity with excitotoxic injury assessed by cresyl violet staining. Results are from one out of two independent experiments.
Figure 5. Endogenous CSF1 is up-regulated in neurons after excitotoxic brain injury. (A–C) Wild-type FVB/N or CSF1-null Csf1op/op mice (2 mo old) were lesioned with 20 mg/kg KA (subcutaneous injection) and sacrificed 6 h, 1 d, and 3 d later. Brain sections were immunostained with an antibody against CSF1. (A) Representative images from wild-type controls (no injury), KA lesioned and sacrificed at 6 h, KA lesioned and sacrificed at 24 h, or Csf1op/op mice. (B) Quantification of CSF1 immunoreactivity in the hippocampus after KA injury (n = 4–6 mice/group). Error bars indicate SEM. (C) Colocalization of CSF1 and neuronal marker NeuN but not microglial marker (Iba-1) after KA lesion (6 h). Bars: (A) 200 µm; (C) 20 µm. (D) Inverse correlation (Pearson correlation) of CSF1 immunoreactivity with excitotoxic injury assessed by cresyl violet staining. Results are from one out of two independent experiments.CC BY-NC-SA · PubMed Central
Figure 6. Expression of CSF1R in neurons. (A–D) Detection of Csf1r mRNA in the hippocampus using in situ hybridization. Wild-type FVB/N mice were lesioned with 20 mg/kg KA (subcutaneous injection) or injected with PBS as a control and sacrificed 24 h later. Brain sections were hybridized with DIG-labeled antisense (A and B) or sense (C and D) probes for Csf1r and developed with an anti-DIG antibody. No signal was detected with the sense probe (C and D). Arrows point to cells expressing CSF1R, as detected by in situ hybridization. (E–H) CSF1R reporter mice (MAFIA mice, 2 mo of age) were lesioned with 20 mg/kg KA (subcutaneous injection) or injected with PBS as control and sacrificed 6 and 24 h later. These mice express an EGFP tag under the control of the Csf1r promoter so that the expression of CSF1R can be detected by GFP immunostaining. (E) To test the specificity of the antibody against GFP, brain sections from MAFIA mice (not injured, left), wild-type mice (middle), and wild-type mice with KA injury (right) were immunostained. (F) Representative images of different brain regions from MAFIA mice injected with PBS and sacrificed 24 h later (left) or injected with KA and sacrificed at 6 (middle) or 24 (right). (G) High-magnification images showing GFP immunoreactivity in microglia (left) and neurons (middle and right), determined by morphology. Arrows point to cells expressing CSF1R, as detected by immunohistochemistry for the reporter gene. (H) 2-mo-old MAFIA mice received unilateral stereotaxic injections of 50 ng KA (right hemibrain) or PBS (left hemibrain). Mice were sacrificed 6 h later, and brain sections were analyzed for reporter gene expression by GFP immunostaining. The data are representative of two independent experiments with n = 3 mice/group. Bars: (A–D) 50 µm; (E, F, and H) 200 µm; (G) 10 µm.
Figure 6. Expression of CSF1R in neurons. (A–D) Detection of Csf1r mRNA in the hippocampus using in situ hybridization. Wild-type FVB/N mice were lesioned with 20 mg/kg KA (subcutaneous injection) or injected with PBS as a control and sacrificed 24 h later. Brain sections were hybridized with DIG-labeled antisense (A and B) or sense (C and D) probes for Csf1r and developed with an anti-DIG antibody. No signal was detected with the sense probe (C and D). Arrows point to cells expressing CSF1R, as detected by in situ hybridization. (E–H) CSF1R reporter mice (MAFIA mice, 2 mo of age) were lesioned with 20 mg/kg KA (subcutaneous injection) or injected with PBS as control and sacrificed 6 and 24 h later. These mice express an EGFP tag under the control of the Csf1r promoter so that the expression of CSF1R can be detected by GFP immunostaining. (E) To test the specificity of the antibody against GFP, brain sections from MAFIA mice (not injured, left), wild-type mice (middle), and wild-type mice with KA injury (right) were immunostained. (F) Representative images of different brain regions from MAFIA mice injected with PBS and sacrificed 24 h later (left) or injected with KA and sacrificed at 6 (middle) or 24 (right). (G) High-magnification images showing GFP immunoreactivity in microglia (left) and neurons (middle and right), determined by morphology. Arrows point to cells expressing CSF1R, as detected by immunohistochemistry for the reporter gene. (H) 2-mo-old MAFIA mice received unilateral stereotaxic injections of 50 ng KA (right hemibrain) or PBS (left hemibrain). Mice were sacrificed 6 h later, and brain sections were analyzed for reporter gene expression by GFP immunostaining. The data are representative of two independent experiments with n = 3 mice/group. Bars: (A–D) 50 µm; (E, F, and H) 200 µm; (G) 10 µm.CC BY-NC-SA · PubMed Central
Figure 7. CSF1R reporter gene is expressed in neurons and up-regulated after excitotoxic brain injury. (A–D) CSF1R reporter mice (MAFIA mice, 2 mo of age) were lesioned with 20 mg/kg KA (subcutaneous injection) or injected with PBS as control and sacrificed 6 h later. Representative confocal microscopy images from control (PBS; A and C) and KA-lesioned mice (B and D) double immunolabeled with antibodies against GFP and cell type–specific markers Iba-1 (microglia; A and B) and NeuN (neurons; C and D). The reporter gene–expressing cells appear yellow after superimposition. An Iba-1 immuno-negative cell that expresses the reporter gene is shown (arrow) in A. Up-regulation of the reporter gene in neurons is shown after KA lesion (D) compared with control (C). The data are representative of two independent experiments with n = 3 mice/group. (E) Csf1r-iCre mice were crossed with mTmG mice. Cre recombinase expression driven by the endogenous Csf1r promoter leads to expression of EGFP in double transgenic mice. Representative confocal microscopy images from control (PBS; left) and KA-lesioned mice (right) 6 h after injury double immunolabeled with antibodies against GFP (green) and neuron-specific marker NeuN (blue). This experiment was performed once with n = 5 mice/group. Bars, 20 µm.
Figure 7. CSF1R reporter gene is expressed in neurons and up-regulated after excitotoxic brain injury. (A–D) CSF1R reporter mice (MAFIA mice, 2 mo of age) were lesioned with 20 mg/kg KA (subcutaneous injection) or injected with PBS as control and sacrificed 6 h later. Representative confocal microscopy images from control (PBS; A and C) and KA-lesioned mice (B and D) double immunolabeled with antibodies against GFP and cell type–specific markers Iba-1 (microglia; A and B) and NeuN (neurons; C and D). The reporter gene–expressing cells appear yellow after superimposition. An Iba-1 immuno-negative cell that expresses the reporter gene is shown (arrow) in A. Up-regulation of the reporter gene in neurons is shown after KA lesion (D) compared with control (C). The data are representative of two independent experiments with n = 3 mice/group. (E) Csf1r-iCre mice were crossed with mTmG mice. Cre recombinase expression driven by the endogenous Csf1r promoter leads to expression of EGFP in double transgenic mice. Representative confocal microscopy images from control (PBS; left) and KA-lesioned mice (right) 6 h after injury double immunolabeled with antibodies against GFP (green) and neuron-specific marker NeuN (blue). This experiment was performed once with n = 5 mice/group. Bars, 20 µm.CC BY-NC-SA · PubMed Central
Figure 8. CSF1 maintains CREB phosphorylation. (A–D) CSF1 maintains CREB phosphorylation after KA lesion. Wild-type FVB/N mice (n = 4 per group, 2 mo of age) were lesioned with 20 mg/kg KA (subcutaneous injection) or injected with PBS as control. For treatment, CSF1 or PBS was applied 24 h before KA. Mice were sacrificed 6 h after KA injection. One hemibrain was fixed for immunohistochemistry with an antibody against p-CREB (A, left and middle), and p-CREB immunoreactivity was quantified as percentage of area occupied (B). The opposite hippocampi were isolated and subjected to Western blot analysis for p-CREB (C), which was quantified as optical intensity (D). Results are from one out of two independent experiments. (E and F) CSF1 restores CREB signaling in hAPP mice. hAPP mice and their nTG littermates (Fig. 1 A) were treated with 800 µg/kg CSF1 or PBS three times a week. 10 wk later, the mice were sacrificed after water maze behavior test, and one hemibrain was analyzed by immunohistochemistry for p-CREB immunoreactivity. The experiment was performed once. Error bars indicate SEM. Bars: (A, left) 200 µm; (A [middle and right] and E) 50 µm. *, P < 0.05; **, P < 0.01 compared by ANOVA and Bonferroni post-hoc test (B and F) or Student’s t test (D).
Figure 8. CSF1 maintains CREB phosphorylation. (A–D) CSF1 maintains CREB phosphorylation after KA lesion. Wild-type FVB/N mice (n = 4 per group, 2 mo of age) were lesioned with 20 mg/kg KA (subcutaneous injection) or injected with PBS as control. For treatment, CSF1 or PBS was applied 24 h before KA. Mice were sacrificed 6 h after KA injection. One hemibrain was fixed for immunohistochemistry with an antibody against p-CREB (A, left and middle), and p-CREB immunoreactivity was quantified as percentage of area occupied (B). The opposite hippocampi were isolated and subjected to Western blot analysis for p-CREB (C), which was quantified as optical intensity (D). Results are from one out of two independent experiments. (E and F) CSF1 restores CREB signaling in hAPP mice. hAPP mice and their nTG littermates (Fig. 1 A) were treated with 800 µg/kg CSF1 or PBS three times a week. 10 wk later, the mice were sacrificed after water maze behavior test, and one hemibrain was analyzed by immunohistochemistry for p-CREB immunoreactivity. The experiment was performed once. Error bars indicate SEM. Bars: (A, left) 200 µm; (A [middle and right] and E) 50 µm. *, P < 0.05; **, P < 0.01 compared by ANOVA and Bonferroni post-hoc test (B and F) or Student’s t test (D).CC BY-NC-SA · PubMed Central
Figure 9. Recombinant CSF1 and IL-34 inhibit excitotoxic injury and activate the CREB pathway in vitro. (A) Detection of Csf1r mRNA by in situ hybridization in cultured primary neurons. Primary hippocampal neurons were isolated from 16-d-old CF1 mouse embryos, aged for 6–7 d and hybridized with DIG-labeled Csf1r sense (top) or antisense (bottom) probes. (B–F) Primary hippocampal neurons were isolated from 16-d-old CF1 mouse embryos and were aged for 6–7 d (B and C) or 21–22 d (D–F). (B) Primary neurons were exposed to 1 or 100 ng/ml IL-34, 1 or 100 ng/ml CSF1, 10 µM Forskolin (FSK, as a positive control), or PBS (as a negative control) for 30 min. The cells were lysed and subjected to Western blot analysis for p-CREB. (C–F) Primary neurons were challenged with 100 µM NMDA in the presence and absence of CSF1 or IL-34 (both at 10 ng/ml) and assayed for neurotoxicity (C) or neuritic dystrophy (D–F), respectively. For inhibitor experiments, 10 µM GW2580 was coincubated with CSF1 or IL-34. (C) Live and dead cells were counted according to their morphologies determined by phase-contrast microscopy. Results are expressed as percentage of live cells. (D–F) Neurons were fixed and immunostained for MAP-2 to visualize dendrites. Dystrophic neurites in NMDA-treated cultures show increased tortuosity, exhibiting multiple abrupt turns (D, bracket). The number of dystrophic neurites (E) and their mean differential curvature (F) are reduced with CSF1 or IL-34 treatment. Error bars indicate SEM. Bars, 20 µm. *, P < 0.05; **, P < 0.01 compared by ANOVA and Tukey’s post-hoc test. The experiments were independently performed five times for B and twice for the rest with triplicates of each group.
Figure 9. Recombinant CSF1 and IL-34 inhibit excitotoxic injury and activate the CREB pathway in vitro. (A) Detection of Csf1r mRNA by in situ hybridization in cultured primary neurons. Primary hippocampal neurons were isolated from 16-d-old CF1 mouse embryos, aged for 6–7 d and hybridized with DIG-labeled Csf1r sense (top) or antisense (bottom) probes. (B–F) Primary hippocampal neurons were isolated from 16-d-old CF1 mouse embryos and were aged for 6–7 d (B and C) or 21–22 d (D–F). (B) Primary neurons were exposed to 1 or 100 ng/ml IL-34, 1 or 100 ng/ml CSF1, 10 µM Forskolin (FSK, as a positive control), or PBS (as a negative control) for 30 min. The cells were lysed and subjected to Western blot analysis for p-CREB. (C–F) Primary neurons were challenged with 100 µM NMDA in the presence and absence of CSF1 or IL-34 (both at 10 ng/ml) and assayed for neurotoxicity (C) or neuritic dystrophy (D–F), respectively. For inhibitor experiments, 10 µM GW2580 was coincubated with CSF1 or IL-34. (C) Live and dead cells were counted according to their morphologies determined by phase-contrast microscopy. Results are expressed as percentage of live cells. (D–F) Neurons were fixed and immunostained for MAP-2 to visualize dendrites. Dystrophic neurites in NMDA-treated cultures show increased tortuosity, exhibiting multiple abrupt turns (D, bracket). The number of dystrophic neurites (E) and their mean differential curvature (F) are reduced with CSF1 or IL-34 treatment. Error bars indicate SEM. Bars, 20 µm. *, P < 0.05; **, P < 0.01 compared by ANOVA and Tukey’s post-hoc test. The experiments were independently performed five times for B and twice for the rest with triplicates of each group.CC BY-NC-SA · PubMed Central
Figure 10. Deletion of CSF1R in neurons reduces p-CREB immunoreactivity and increases susceptibility to excitotoxic injury. Csf1rf/f-cre mice and their control littermates (2 mo of age) were lesioned with a unilateral stereotaxic injection of 50 ng KA or PBS as control into the hippocampus. (A and B) Mice were sacrificed 24 h later, and brain sections were analyzed for p-CREB immunoreactivity, quantified as percentage of area occupied (n = 3 mice/group). The boxes in A indicate the corresponding hippocampal areas shown in the panel below (with higher magnification). (C–J) Mice were sacrificed 5 d later, and brain sections were analyzed for neuronal injury by cresyl violet staining (C and D), calbindin immunostaining (E and F), and CD68 or Iba-1 immunostaining (microglial activation; G–J). In C, E, G, and I, mice from the control (top) and Csf1rf/f-cre mice (bottom) are shown. Bars, 200 µm. Bars are mean ± SEM (n = 3–4 mice/group) from one out of two independent experiments. *, P < 0.05; **, P < 0.01 compared with control by Student’s t test.
Figure 10. Deletion of CSF1R in neurons reduces p-CREB immunoreactivity and increases susceptibility to excitotoxic injury. Csf1rf/f-cre mice and their control littermates (2 mo of age) were lesioned with a unilateral stereotaxic injection of 50 ng KA or PBS as control into the hippocampus. (A and B) Mice were sacrificed 24 h later, and brain sections were analyzed for p-CREB immunoreactivity, quantified as percentage of area occupied (n = 3 mice/group). The boxes in A indicate the corresponding hippocampal areas shown in the panel below (with higher magnification). (C–J) Mice were sacrificed 5 d later, and brain sections were analyzed for neuronal injury by cresyl violet staining (C and D), calbindin immunostaining (E and F), and CD68 or Iba-1 immunostaining (microglial activation; G–J). In C, E, G, and I, mice from the control (top) and Csf1rf/f-cre mice (bottom) are shown. Bars, 200 µm. Bars are mean ± SEM (n = 3–4 mice/group) from one out of two independent experiments. *, P < 0.05; **, P < 0.01 compared with control by Student’s t test.CC BY-NC-SA · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Cited by

See all 281

Metadata

Authors
Luo, J., Elwood, F., Britschgi, M., Villeda, S., Zhang, H., Ding, Z., Zhu, L., Alabsi, H., Getachew, R., Narasimhan, R., Wabl, R., Fainberg, N., James, M. L., Wong, G., Relton, J., Gambhir, S. S., Pollard, J. W., & Wyss-Coray, T.
Affiliations
  • Stanford Medicine (US)
  • Albert Einstein College of Medicine (US)
  • Biogen (United States) (US)
  • Department of Neurology and Neurological Sciences 1 and 2
Venue
Journal of Experimental Medicine
Published
2013-01-07
Volume
210
Issue
1
Pages
157-172
ISSN
  • 0022-1007 (ISSN-L)
  • 1540-9538
OpenAlex
W2171223421
Cited by
262
References
80
Citations by year
2026: 10 · 2025: 14 · 2024: 21 · 2023: 15 · 2022: 16 · 2021: 43 · 2020: 24 · 2019: 29 · 2018: 22 · 2017: 20 · 2016: 16 · 2015: 12 · 2014: 16 · 2013: 4
FWCI
8.96
Type
journal article
Language
en
Open access
Locations
  • The Journal of Experimental Medicine (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
  • Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, cc-by-nc-sa)
Funders
  • Biogen
  • National Institutes of Health
  • National Institute on Aging (R21AG023708, AG20603, AG23708, R01AG020603)
Topics
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Clinical Neurology › Traumatic Brain Injury and Neurovascular Disturbances
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords
CSF-1 receptor, CSF-1, IL-34, neuroprotection, excitotoxicity, neurodegeneration, CREB signaling, hippocampus, cortex, gliosis, monocyte/macrophage lineage
MeSH terms
Animals, Base Sequence, Cell Survival, Cognition, Disease Models, Animal, Humans, Interleukins, Kainic Acid, Mice, Inbred C57BL, Mice, Transgenic, Molecular Sequence Data, Neurons, Phosphorylation, Recombinant Proteins, Signal Transduction, Macrophage Colony-Stimulating Factor, Receptor, Macrophage Colony-Stimulating Factor, Prosencephalon, Amyloid beta-Protein Precursor, Cyclic AMP Response Element-Binding Protein, Neuroprotective Agents, Neurodegenerative Diseases, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.